Cardiovascular and hepatic disease associations by magnetic resonance imaging: A retrospective cohort study.
FIB-4
NAFLD
cardiac MRI
hepatic fibrosis
liver disease
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
08
2022
accepted:
29
09
2022
entrez:
3
11
2022
pubmed:
4
11
2022
medline:
4
11
2022
Statut:
epublish
Résumé
Hepatic disease is linked to cardiovascular events but the independent association between hepatic and cardiovascular disease remains unclear, given shared risk factors. This was a retrospective study of consecutive patients with a clinical cardiac MRI (CMR) and a serological marker of hepatic fibrosis, the FIB-4 score, within one year of clinical imaging. We assessed the relations between FIB-4 scores grouped based on prior literature: low (< 1.3), moderate (1.3-3.25), and high (>3.25), and abnormalities detected by comprehensive CMR grouped into 4 domains: cardiac structure (end diastolic volumes, atrial dimensions, wall thickness); cardiac function (ejection fractions, wall motion abnormalities, cardiac output); vascular structure (ascending aortic and pulmonary arterial sizes); and cardiac composition (late gadolinium enhancement, T1 and T2 times). We used Poisson regression to examine the association between the conventionally defined FIB-4 category (low <1.3, moderate 1.3-3.25, and high >3.25) and any CMR abnormality while adjusting for demographics and traditional cardiovascular risk factors. Of the 1668 patients studied (mean age: 55.971 ± 7.28, 901 [54%] male), 85.9% had ≥1 cardiac abnormality with increasing prevalence seen within the low (82.0%) to moderate (88.8%) to high (92.3%) FIB-4 categories. Multivariable analyses demonstrated the presence of any cardiac abnormality was significantly associated with having a high-range FIB-4 (prevalence ratio 1.07, 95% CI: 1.01-1.13); notably, the presence of functional cardiac abnormalities were associated with being in the high FIB-4 range (1.41, 1.21-1.65) and any vascular abnormalities with being in the moderate FIB-4 range (1.22, 1.01-1.47). Elevated FIB-4 was associated with cardiac functional and vascular abnormalities even after adjustment for shared risk factors in a cohort of patients with clinically referred CMR. These CMR findings indicate that cardiovascular abnormalities exist in the presence of subclinical hepatic fibrosis, irrespective of shared risk factors, underscoring the need for further studies of the heart-liver axis.
Sections du résumé
Background
UNASSIGNED
Hepatic disease is linked to cardiovascular events but the independent association between hepatic and cardiovascular disease remains unclear, given shared risk factors.
Methods
UNASSIGNED
This was a retrospective study of consecutive patients with a clinical cardiac MRI (CMR) and a serological marker of hepatic fibrosis, the FIB-4 score, within one year of clinical imaging. We assessed the relations between FIB-4 scores grouped based on prior literature: low (< 1.3), moderate (1.3-3.25), and high (>3.25), and abnormalities detected by comprehensive CMR grouped into 4 domains: cardiac structure (end diastolic volumes, atrial dimensions, wall thickness); cardiac function (ejection fractions, wall motion abnormalities, cardiac output); vascular structure (ascending aortic and pulmonary arterial sizes); and cardiac composition (late gadolinium enhancement, T1 and T2 times). We used Poisson regression to examine the association between the conventionally defined FIB-4 category (low <1.3, moderate 1.3-3.25, and high >3.25) and any CMR abnormality while adjusting for demographics and traditional cardiovascular risk factors.
Results
UNASSIGNED
Of the 1668 patients studied (mean age: 55.971 ± 7.28, 901 [54%] male), 85.9% had ≥1 cardiac abnormality with increasing prevalence seen within the low (82.0%) to moderate (88.8%) to high (92.3%) FIB-4 categories. Multivariable analyses demonstrated the presence of any cardiac abnormality was significantly associated with having a high-range FIB-4 (prevalence ratio 1.07, 95% CI: 1.01-1.13); notably, the presence of functional cardiac abnormalities were associated with being in the high FIB-4 range (1.41, 1.21-1.65) and any vascular abnormalities with being in the moderate FIB-4 range (1.22, 1.01-1.47).
Conclusions
UNASSIGNED
Elevated FIB-4 was associated with cardiac functional and vascular abnormalities even after adjustment for shared risk factors in a cohort of patients with clinically referred CMR. These CMR findings indicate that cardiovascular abnormalities exist in the presence of subclinical hepatic fibrosis, irrespective of shared risk factors, underscoring the need for further studies of the heart-liver axis.
Identifiants
pubmed: 36324754
doi: 10.3389/fcvm.2022.1009474
pmc: PMC9618632
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1009474Informations de copyright
Copyright © 2022 Kwan, Sun, Driver, Botting, Navarrette, Ouyang, Hussain, Noureddin, Li, Ebinger, Berman and Cheng.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Postgrad Med J. 2009 Jan;85(999):44-54
pubmed: 19240290
Hepatol Res. 2016 Aug;46(9):862-70
pubmed: 26763834
J Clin Invest. 1953 Oct;32(10):1025-33
pubmed: 13096569
PLoS One. 2021 Jul 22;16(7):e0254939
pubmed: 34293022
Hepatology. 1995 Aug;22(2):472-8
pubmed: 7635415
Diagnostics (Basel). 2021 Nov 29;11(12):
pubmed: 34943471
J Cardiovasc Magn Reson. 2010 Aug 13;12:47
pubmed: 20704762
Radiology. 2020 Oct;297(1):51-61
pubmed: 32808886
World J Gastroenterol. 2006 Feb 14;12(6):837-42
pubmed: 16521209
Gut. 2018 Jan;67(1):6-19
pubmed: 29122851
J Cardiovasc Magn Reson. 2020 Nov 9;22(1):76
pubmed: 33161900
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
J Cardiovasc Magn Reson. 2020 Dec 14;22(1):87
pubmed: 33308262
Gut. 2010 Sep;59(9):1265-9
pubmed: 20801772
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Gut. 2000 Jan;46(1):1-4
pubmed: 10601042
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
J Hepatol. 2013 Apr;58(4):757-62
pubmed: 23178979
J Hepatol. 2018 Nov;69(5):1015-1024
pubmed: 29886155
Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44
pubmed: 23507799
Clin Liver Dis (Hoboken). 2021 Feb 01;17(1):23-28
pubmed: 33552482
Front Med (Lausanne). 2019 Sep 13;6:202
pubmed: 31616668